MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Akero Therapeutics, Inc. (Nasdaq: AKRO)*
Finance & Acquisitions: Akero
Parents
Akero Therapeutics, Inc. (Nasdaq: AKRO)*
Children
2018: They were joined by Redmile Group, Boxer Capital of Tavistock Group, Cormorant Asset Management, BVF Partners, Rock Springs Capital, and LifeSci Venture Partners.
2018: Akero’s series A backers Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures returned for the B round.
2018: NASH-focused Akero Therapeutics adds another $70M to the bank
2025: Akero: Novo Nordisk Acquisition Puts Focus On Unprecedented MASH Data With EFX (AKRO)
2025: Novo Nordisk Snaps Up MASH Player Akero For Up To $5.2 Billion
Jumps
Key People: Akero
Organization & Developments: Akero